Get all premium features to the best stock analysis tool

In the most recent trading session, Zoetis (ZTS) closed at $113.35, indicating a -2.81% shift from the previous trading day.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zoetis Inc. (ZTS) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript

Zoetis Inc. (ZTS) is a wide-moat animal health leader, rated BUY due to strong fundamentals and undervaluation despite industry-leading profitability. Zoetis trades at a forward P/E of 17.28x, below both S&P 500 and weaker rival Elanco, with a target price of $150 implying 25% upside. Risks center on Librela/Solensia safety concerns, with FDA post-marketing study results in 1H 2026 being a critical near-term catalyst.

The heavy selling pressure might have exhausted for Zoetis (ZTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?